{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041269","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.997832+00:00","generated_at":"2026-05-16T22:25:10.720943+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Roivant Q2 net loss $113.5M; brepocitinib Phase 3 DM trial succeeds on all endpoints","bullets":["Brepocitinib 30 mg met primary and all nine key secondary endpoints in Phase 3 VALOR DM study; NDA filing planned H1 2026.","Net loss attributable to Roivant $113.5M ($0.17/sh) vs $230.2M ($0.31) a year ago; revenue $1.6M.","Cash and marketable securities $4.4B as of Sept 30, 2025; R&D spend $164.6M (up 15% YoY).","Immunovant batoclimab TED: first Phase 3 readout by end-2025, but both studies to release concurrently in H1 2026 due to competitive dynamics.","Favorable Markman ruling in Pfizer/BioNTech LNP litigation; Moderna jury trial scheduled March 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041269","json":"https://secwatch.observer/filing/0001140361-25-041269.json","markdown":"https://secwatch.observer/filing/0001140361-25-041269.md","text":"https://secwatch.observer/filing/0001140361-25-041269.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125041269/0001140361-25-041269-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036125041269/ef20058314_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:25:10.720943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}